巯基十二硼烷二钠盐的急性毒性与药代动力学研究

doi:10.7538/tws.2016.29.03.0164

摘要/Abstract

摘要：

本研究采用210、300、430、614 mg/kg四个剂量对巯基十二硼烷二钠盐（BSH）进行了急性毒性实验，得到其半数致死量（LD₅₀）为381.94 mg/kg，LD₅₀的95%置信区间为［334.97 mg/kg，435.51 mg/kg］。进行BSH的药代动力学初步研究，根据给药后得到的药时曲线，选用三房室模型拟合得到BSH的半衰期分别为t_1/2α=3.6 min、t_1/2β=55.8 min、t_1/2γ=6.26 h；表观分布容积Vd为3 523.58 mL/kg、药时曲线面积AUC为247.55 hr*μg/mL、清除率CL为3 572.45 mL/hr/kg。在小鼠体内的生物分布结果表明，BSH在血液中清除较快，各器官在注射后30 min达到最大摄取，其在体内主要通过肾脏排泄。以上研究结果可为BSH在国内临床应用的安全性提供实验基础。

关键词: BNCT, BSH, 急性毒性, 药代动力学, 生物分布

Abstract:

In this study, the acute toxicity of BSH was studied at doses of 210, 300, 430, 614 mg/kg, and the LD₅₀ was calculated at 381.94 mg/kg. A three-compartment model system was used to evaluate the pharmacokinetics of the BSH, and the pharmacokinetic parameters, such as t_1/2，Vd, AUC, CL of BSH were calculated: t_1/2α=3.6 min, t_1/2β=55.8 min, t_1/2γ=6.26 h, Vd=3 523.58 mL/kg, AUC= 247.55 hr*μg/mL, CL=3572.45 mL/hr/kg. The biodistribution of the BSH was studied in normal mice, from which the characteristics of biodistribution of BSH was analyzed.

Key words: BNCT, BSH, acute toxicity, pharmacokinetics, biodistribution

李凤林;罗志福;樊彩云;刘子华;邓新荣. 巯基十二硼烷二钠盐的急性毒性与药代动力学研究[J]. 同位素, 2016, 29(3): 164-169.

LI Feng-lin;LUO Zhi-fu;FAN Cai-yun;LIU Zi-hua;DENG Xin-rong. The Acute Toxicity and Pharmacokinetics of the BSH[J]. Journal of Isotopes, 2016, 29(3): 164-169.

参考文献

［1］Barth R F, Coderre J A, Vicente G H, et al. Boron neutron capture therapy of cancer: current status and future prospects［J］. Clin Cancer Res, 2005, 11(11): 3987-4002.
［2］Farr L E, Sweet W H, Robertson J S, et al. Neutron capture therapy with boron in the treatment of glioblastoma multiforme［J］. Am J Roentgenol, 1954, 71: 279-291.
［3］Barth R F, Yang W, Coderre J A. Rat brain tumor models to assess the efficacy of boron neutron capture therapy: a critical evaluation［J］. J Neuro-oncol, 2003, 62(1): 61-74.
［4］Oterson B, Haritz D, Grochulla M, et al. Binding and distribution of Na₂B₁₂H₁₁SH on cellular and subcellular level in tumor tissue of glioma patients in boron neutron capture therapy［J］. J Neuro-oncol, 1997, 33(1/2): 131-139.
［5］Soloway A H, Hatanaka H, Davis M A. Penetration of brain and brain tumor. Ⅶ. Tumor binding sulfhydryl boron compounds［J］.J Med Chem, 1967, 10(4): 714-717.
［6］Hatanaka H. A revised boron neutron capture therapy for malignant brain tumors-Ⅱ in clinical result with the patients excluding previous treatments［J］. J Neuro-oncol, 1975, 209(2): 81-94.
［7］Hatanaka H, Nakagawa Y. Clinical results of long-surviving brain tumor patients who underwent boron neutron capture therapy［J］. Int J Radiat Oncol Biol Phys, 1994, 28(5): 1061-1066.
［8］Nakagawa Y, Hatanaka H. Boron neutron capture therapy——clinical brain tumor study［J］. J Neurooncol, 1997, 33(1/2): 105-115.
［9］Masunaga S, Nagasawa H, Hiraoka M. The usefulness of 2-nitroimidazole-sodium borocaptate-¹⁰B conjugates as ¹⁰B-carriers in boron neutron capture therapy［J］. Appl Radiat Isot, 2004, 61 (5): 953-958.
［10］Garabalino M A, Heber E M, Hughes A M, et al. Biodistribution of sodium borocaptate (BSH) for boron neutron capture therapy (BNCT) in an oral cancer model［J］.Biophysik, 2013, 52(3): 351-361.
［11］Micnihiro K, Katsutoshi A, Koichiro N, et al. A Convenient Preparation of B₁₂H₁₁SH^-₂ for Boron Neutron Capture Therapy［J］. Chem Express, 1987, 2 (3): 173.
［12］Christopher R G, Alfred E S, Barth R F, et al. Pharmacokinetics of sodium boroncaptate: a critical assessment of dosing paradigms for boron neutron capture therapy［J］. J Neuro-oncol, 2003, (62): 157-169.
［13］Fairchild R G, Kahl S B, Laster B H, et al. In vitro determination of uptake, retention, distribution, biological efficiency, and toxicity of boronated compounds for neutron capture therapy: a comparison of porphyrins with sulfhydryl boron hydrides［J］.Cancer Res, 1990, 50(16) : 4860-4865.
［14］Ceberg C P, Brun A, Kahl S B, et al. A comparative study on the pharmacokinetics and biodistribution of boronated porpyrin(BOPP) and sulfhydryl boron hydride (BSH)in the RG2 rat glioma model［J］. Journal of Neurosurgery, 1995, 83(1): 86-92.
［15］Haselsberger K, Radner H, Pendl G. Boron neutron capture therapy: boron biodistribution and pharmacokinetic of Na₂B₁₂H₁₁SH in patients with glioblastoma［J］.Cancer Res, 1994, 54: 6318-6320.
［16］李凤林,罗志福,邓新荣,等. 分光光度法测量生物组织中BPA含量［J］. 同位素,2013,26(3):163-169.Li fenglin, Luo zhifu, Deng xinrong, et al. Determinate the BPA in biological samples by spectrophotometry［J］. J Isotopes, 2013, 26(3): 163-169(in Chinese).

[1]	马晶鑫;伍洲;姜申德;王红亮;武志芳. 肿瘤PET分子探针3-O-(2-¹⁸F-氟乙基)-L-多巴的合成及初步生物学评价[J]. 同位素, 2018, 31(5): 310-317.
[2]	黄钱焕;潘栋辉;徐宇平;盛洁;王彦婷;杨敏. ⁶⁸Ge/⁶⁸Ga发生器的临床应用[J]. 同位素, 2017, 30(4): 270-275.
[3]	李彦鹏;温馨;程兵;谢新立;杜晓光;韩星敏. (N-［¹⁸F］氟甲基)-胆碱的自动化合成及其生物分布研究[J]. 同位素, 2017, 30(1): 29-35.
[4]	王蕾;张晓军;周艳丽;张锦明. ¹⁸F-FDG-(OAc)₄在¹⁸F-FDG中的残留及在小鼠体内的生物分布[J]. 同位素, 2017, 30(1): 36-42.
[5]	雷晓;朱晓霞;王德才;孟志云;甘慧;顾若兰;吴卓娜;郑颖;李俭;吕明;窦桂芳. ¹²⁵I-MIL50在大鼠体内的药代动力学及生物分布[J]. 同位素, 2016, 29(2): 65-70.
[6]	韩振义;梁积新;胡骥;罗洪义;卿晶;陈玉清;李光;李洪玉. ⁶⁴Cu标记两种奥曲肽类似物的比较[J]. 同位素, 2016, 29(2): 82-88.
[7]	马欢;唐禹;杨远友;刘宁;廖家莉;杨吉军. ¹³¹I标记新型小分子肽VP2[J]. 同位素, 2016, 29(1): 1-5.
[8]	罗洪义;沈浪涛;梁积新;杨春慧;张文辉;秦少鹏;卫成军;刘海春;王建华;李洪玉. ^99mTc-帕米膦酸盐的制备及骨分布[J]. 同位素, 2016, 29(1): 6-11.
[9]	彭程;崔孟超;梁志刚;刘亭廷;张晓阳. ¹²⁵I标记的二噻吩查尔酮类Aβ斑块显像剂的制备与生物评价[J]. 同位素, 2015, 28(4): 253-258.
[10]	张锦明;张晓军;黄德晖;王卉;刘健;田嘉禾. 多发性硬化症显像剂¹¹C-CIC的合成[J]. 同位素, 2015, 28(4): 259-264.
[11]	马秀凤;张君丽;李洪玉;梁积新;杨云;杨春慧;杜进. ¹⁷⁷Lu标记单克隆抗体Rituximab[J]. 同位素, 2014, 27(2): 98-103.
[12]	李贵平;黄宝丹;杜丽;韩彦江;张辉;黄凯;郑文莉. 新型肺癌小分子多肽的¹³¹I标记及其在小鼠体内的生物分布[J]. 同位素, 2014, 27(2): 104-108.
[13]	李凤林;罗志福;邓新荣;樊彩云;刘子华;吴猛. 分光光度法测量生物组织中BPA含量[J]. 同位素, 2013, 26(3): 163-169.
[14]	彭程;牟甜甜;赵祚全;马云川;张现忠. ¹⁸F标记哒嗪酮类似物的制备及其在小鼠体内的生物分布[J]. 同位素, 2013, 26(1): 23-28.
[15]	邓新荣 ;向学琴 ;李凤林 ;樊彩云 ;刘子华 ;陈阳 ;罗志福 . ¹⁷⁷Lu-DOTMP在荷瘤小鼠体内的生物分布和兔SPECT显像研究[J]. 同位素, 2012, 25(3): 160-164.